10月18日，在全球财富管理论坛·2025上海苏河湾大会上，上交所副理事长霍瑞戎表示，新一轮科技革 命正在加速演进，人工智能、生物医药等技术快速发展，不仅会深度影响社会经济活动，也将深刻改 变"科技—产业—金融"的融合发展态势。 霍瑞戎表示，为顺应这一趋势，上交所将始终锚定服务国家战略、推动高质量发展为目标，持续提升上 市公司质量，营造长期资金入市的良好生态，不断增强市场的包容性、适应性和吸引力。 二是以转型升级为驱动，积极更新旧功能。鼓励传统行业运用新技术加快实现转型升级，上半年沪市传 统产业钢铁、机械以技术创新为驱动，持续向高端智能跃升，钢铁和机械等传统行业净利润分别提升 235%和21%。 三是多措并举活跃并购重组，支持新旧动能转换。积极落实"并购六条"，支持上市公司用好用足并购重 组工具，加快实现产业整合和转型升级。今年以来，沪市上市公司披露资产重组602单，其中重大资产 重组76单，较上年分别增长19%和117%。 "投融资协调发展"方面，上交所主要围绕产品多样化、市场生态和服务精准，支持中长期资金入市，健 全投融资协调发展的市场格局。 霍瑞戎提到，一是持续完善ETF产品谱系，加大中低波动产品创新力 ...

Core Viewpoint - Kailaiying's stock price has experienced fluctuations, with a year-to-date increase of 21.46% but a recent decline over various trading periods, indicating potential volatility in the market [1][2]. Financial Performance - For the period from January to September 2025, Kailaiying achieved a revenue of 4.63 billion yuan, representing a year-on-year growth of 11.82%. The net profit attributable to shareholders was 800 million yuan, reflecting a growth of 12.66% [2]. - Since its A-share listing, Kailaiying has distributed a total of 2.405 billion yuan in dividends, with 1.701 billion yuan distributed over the past three years [3]. Stock Market Activity - As of November 19, Kailaiying's stock price was 91.09 yuan per share, with a market capitalization of 32.846 billion yuan. The stock saw a trading volume of 185 million yuan and a turnover rate of 0.63% [1]. - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) once this year, with the last appearance on August 8, where it recorded a net buy of -180 million yuan [1]. Shareholder Information - As of September 30, 2025, Kailaiying had 60,100 shareholders, an increase of 45.37% from the previous period. The average number of circulating shares per person remained at 0 [2]. - The top shareholders include various funds, with notable increases in holdings from 中欧医疗健康混合A and 香港中央结算有限公司 [3].

11月19日，西藏药业盘中下跌2.00%，截至13:24，报44.55元/股，成交1.05亿元，换手率0.72%，总市值 143.59亿元。 西藏药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：疫苗、创新药、生 物医药、医疗器械、中药等。 截至9月30日，西藏药业股东户数4.54万，较上期增加0.57%；人均流通股7092股，较上期减少0.57%。 2025年1月-9月，西藏药业实现营业收入20.89亿元，同比减少3.96%；归母净利润7.22亿元，同比减少 8.85%。 分红方面，西藏药业A股上市后累计派现22.58亿元。近三年，累计派现15.80亿元。 机构持仓方面，截止2025年9月30日，西藏药业十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股365.85万股，相比上期增加106.82万股。创新药（159992）位居第九大流通股东，持股 158.17万股，为新进股东。南方中证1000ETF（512100）位居第十大流通股东，持股147.59万股，为新 进股东。华夏行业景气混合A（003567）退出十大流通股东之列。 责任编辑：小浪快报 资金流向方面，主力资金净流出 ...

"我国经济发展进入新常态，在科创驱动下，以知识、技术、数据、算力、人才等为代表的新要素和新 资产正成为推动我国经济增长的新动力。"刘健称。 在刘健看来，技术要素的积累将推动我国在人工智能、生物医药、氢能和核聚变能、具身智能、第六代 移动通信等未来产业领域实现突破发展。同时，"十五五"时期数据要素将成为驱动经济增长的新动力。 "十五五"规划建议进一步明确，采取超常规措施，全链条推动集成电路、工业母机、高端仪器、基础软 件、先进材料、生物制造等重点领域关键核心技术攻关取得决定性突破。 赵伟称，这一表述凸显了当前科技竞争的严峻性与我国突破"卡脖子"难题的决心，超常规措施或将体现 在研发投入强度提升、科研体制机制改革、创新生态优化等多个维度。"人工智能+"行动的全面实施或 成重要抓手，旨在抢占人工智能产业应用制高点，全方位赋能千行百业。 2025年全球形势复杂多变，A股市场走出一波上涨行情。那么即将到来的2026年，宏观经济将会如何演 绎，A股市场上涨行情是结束还是蓄势待发？ 11月18日，在申万宏源2026资本市场投资年会上，申万宏源党委书记、董事长刘健称："可以预见，未 来中国经济的增长不再是旧动能的延伸，而是新 ...

资料显示，浙江亨通控股股份有限公司位于浙江省湖州市德清县玉屏路地理信息小镇C15幢，成立日期 1999年5月11日，上市日期1999年11月16日，公司主营业务涉及生物农药、兽药、饲料添加剂产品的生 产与销售、热电联供等相关业务。主营业务收入构成为：电解铜箔67.62%，电与蒸汽16.17%，兽药 16.14%，其他业务0.06%。 11月19日，亨通股份盘中下跌2.05%，截至10:08，报4.30元/股，成交6917.87万元，换手率0.53%，总市 值127.90亿元。 资金流向方面，主力资金净流出922.92万元，特大单买入623.93万元，占比9.02%，卖出1031.25万元， 占比14.91%；大单买入1713.06万元，占比24.76%，卖出2228.67万元，占比32.22%。 亨通股份今年以来股价涨68.63%，近5个交易日涨1.18%，近20日跌5.49%，近60日涨35.65%。 今年以来亨通股份已经1次登上龙虎榜，最近一次登上龙虎榜为8月29日，当日龙虎榜净买入4805.76万 元；买入总计1.46亿元 ，占总成交额比22.97%；卖出总计9786.16万元 ，占总成交额比15.40 ...

Core Viewpoint - Nocera Biopharma's stock has experienced fluctuations, with a year-to-date increase of 95.03% but a recent decline of 4.77% over the past five trading days [1] Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [1] - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and 0.15% each from testing and research services [1] Financial Performance - For the period from January to September 2025, Nocera Biopharma reported a revenue of 1.115 billion yuan, reflecting a year-on-year growth of 59.85%, while the net profit attributable to shareholders was -64.41 million yuan, an increase of 76.61% compared to the previous period [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 8.66% to 16,500, with an average of 0 circulating shares per shareholder [2] - The top ten circulating shareholders include several new entrants, such as Wan Jia You Xuan and Ping An Medical Health, while some previous shareholders have reduced their holdings [3]

Core Viewpoint - Aopu Mai's stock price has experienced fluctuations, with a current decline of 2.01% and a year-to-date increase of 59.83%, indicating volatility in the market while showing strong annual growth in revenue and profit [1][2]. Company Overview - Aopu Mai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company is located in Shanghai and specializes in cell culture products and services [1]. - The revenue composition of Aopu Mai is primarily from products (87.34%), followed by services (12.53%) and other sources (0.13%) [1]. Financial Performance - For the period from January to September 2025, Aopu Mai reported a revenue of 272 million yuan, representing a year-on-year growth of 25.79%. The net profit attributable to the parent company was 49.43 million yuan, showing an impressive increase of 81.48% year-on-year [1]. - Since its A-share listing, Aopu Mai has distributed a total of 173 million yuan in dividends [2]. Shareholder Information - As of September 30, 2025, Aopu Mai had 3,682 shareholders, an increase of 14.63% from the previous period. The average number of circulating shares per shareholder rose by 27.96% to 30,838 shares [1]. - Among the top ten circulating shareholders, notable increases were observed in holdings by institutional investors such as China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A [2].

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.02% on November 19, with a trading price of 34.02 CNY per share, reflecting a significant drop in recent trading days despite a substantial year-to-date increase of 359.11% [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (Sutai) at 59.17%, compound polyethylene glycol electrolyte powder at 33.19%, and others at 7.63% [1] - The company was established on August 16, 2002, and went public on April 15, 2011 [1] Financial Performance - For the period from January to September 2025, Shuyou Shen reported an operating income of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decline of 227.71% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 46,500, a rise of 46.97%, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by the third-largest shareholder, Xingquan Helun Mixed A, by 3.45 million shares, and an increase in holdings by the fifth-largest shareholder, Xingquan Heyi Mixed A, by 338,750 shares [3] Market Activity - The stock has seen significant trading activity, with a net outflow of 29.42 million CNY from major funds on November 19, and it has appeared on the trading leaderboard eight times this year, with the most recent instance on October 31, where it recorded a net buy of 373 million CNY [1]

11月19日，京新药业盘中下跌2.01%，截至09:38，报20.48元/股，成交1.27亿元，换手率0.85%，总市值 176.34亿元。 京新药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：阿尔茨海默、抗癌治 癌、眼科概念、生物医药、创新药等。 截至9月30日，京新药业股东户数2.23万，较上期减少13.08%；人均流通股32438股，较上期增加 15.05%。2025年1月-9月，京新药业实现营业收入30.48亿元，同比减少5.00%；归母净利润5.76亿元，同 比增长0.10%。 分红方面，京新药业A股上市后累计派现21.10亿元。近三年，累计派现8.01亿元。 机构持仓方面，截止2025年9月30日，京新药业十大流通股东中，香港中央结算有限公司位居第七大流 通股东，持股745.88万股，相比上期减少219.04万股。 责任编辑：小浪快报 资金流向方面，主力资金净流出165.99万元，特大单买入628.85万元，占比4.95%，卖出725.96万元，占 比5.71%；大单买入2673.29万元，占比21.04%，卖出2742.17万元，占比21.58%。 京新药业今年以来股价涨64 ...

Group 1 - The core message emphasizes the importance of implementing the spirit of the 20th Central Committee and advancing the "14th Five-Year Plan" while striving for new breakthroughs in the construction of a socialist modern country [1][4] - The focus is on enhancing the role of key scientific facilities in synthetic biology, promoting collaboration between industry and academia, and accelerating the application of synthetic biology technologies in various fields such as healthcare and agriculture [2][4] - The development of the Yantian Port is highlighted as a significant achievement, showcasing the transformation from a barren salt flat to a major port, which is crucial for modern construction and regional economic integration [3][4] Group 2 - The need for Shenzhen to leverage its historical and cultural resources to enhance tourism and create a cross-border consumption brand is emphasized, particularly in the context of the Hong Kong collaboration [3] - The importance of technological innovation and the integration of industries is stressed, with a focus on achieving breakthroughs in artificial intelligence, integrated circuits, biomedicine, and new materials [4] - The preparation for the APEC meeting and the organization of the 15th National Games are highlighted as key tasks, with an emphasis on improving urban governance and ensuring successful event execution [4]